natgillin/translations-raw huggingface dataset:
The dose required to achieve a trough level of 5-6 g/l is of the order of 0.2-0.8 g/kg/month.
Odmerek, s katerim dosežete najnižjo koncentracijo 5-6 g/l, je reda velikosti 0,2-0,8 g/kg/mesec.
The dose required to achieve a trough level of 6 g/l is of the order of 0.4-0.8 g/kg body weight per month.
Odmerek, s katerim dosežete najnižjo koncentracijo 6 g/l, je razreda velikosti od 0,4 do 0,8 g/kg telesne mase na mesec.
The dose schedule should not be intentionally increased above the recommended doses due to the absence of information on the additional risk that may be incurred.
Razporeda odmerekov se ne sme namenoma povečati nad priporočene odmerke, ker ni informacij o dodatnih tveganjih, ki jih to lahko povzroči.
The dose selector clicks differently when turned forward, backward or past the number of dose steps left.
Izbirnik odmerka klika z drugačnim zvokom, ko ga obračate naprej, nazaj ali mimo števila preostalih odmernih korakov.
The dose selector clicks when you turn it.
Izbirnik odmerka pri vrtenju klika.
The dose selector returns to 0.
Izbirnik odmerka se vrne na vrednost 0.
The dose should always be measured using the oral syringe supplied with the bottle.
Odmerek je vedno treba izmeriti s peroralno brizgo, ki je priložena steklenici z zdravilom.
The dose should be adjusted according to the patient’s renal function (see dosage recommendations in renal impairment and section 5.2).
Odmerek je treba prilagoditi glede na delovanje ledvic (glejte priporočila za odmerjanje pri okvari ledvic in poglavje 5.2).
The dose should be adjusted as necessary to maintain the individual target haemoglobin level between 10 g/dl (6.21 mmol/l) to 12 g/dl (7.45 mmol/l), whereby a haemoglobin level of 12 g/dl (7.45 mmol/l) should not be exceeded.
Po potrebi je treba odmerek prilagoditi, da se pri posamezniku vzdržuje ciljna raven hemoglobina od 10 g/dl (6,21 mmol/l) do 12 g/dl (7,45 mmol/l), pri čemer pa se ne sme preseči raven hemoglobina 12 g/dl (7,45 mmol/l).
The dose should be adjusted in patients who are taking other medicines that are broken down in the same way as Abilify.
Odmerek zdravila Abilify je treba prilagoditi pri bolnikih, ki jemljejo druga zdravila, ki se presnavljajo enako kot to zdravilo.
The dose should be adjusted when creatinine clearance (CrCL) is ≤ 50 ml/min, as shown in Tables 3 and 4 (see section 5.2).
Če je očistek kreatinina (CrCL) ≤ 50 ml/min, je treba odmerek prilagoditi, kot prikazujeta preglednici 3 in 4 (glejte poglavje 5.2).
The dose should be administered in two equally divided doses, once in the morning and once in the evening.
Odmerek se daje razdeljen na dva enaka odmerka, enega zjutraj in drugega zvečer.
The dose should be administered using a calibrated dosing syringe.
Za odmerjanje je treba uporabiti kalibrirano odmerno brizgo.
The dose should be calculated based on the patient’s body weight at each administration.
Odmerek je treba izračunati glede na bolnikovo telesno maso pred vsakim dajanjem.
The dose should be delayed or treatment discontinued as necessary in cases of left ventricular dysfunction (see section 4.2).
V primerih disfunkcije levega prekata je treba odmerek preložiti ali zdravljenje prenehati, če je to potrebno (glejte poglavje 4.2).
The dose should be escalated gradually to minimise the incidence and severity of gastrointestinal side effects and aminotransferase elevations.
Odmerek je treba večati postopoma, da se čim bolj zmanjša incidenca in resnost neželenih učinkov na prebavila ter povišanja ravni aminotransferaze.
The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
Nato se ga postopno, v skladu z bolnikovimi individualnimi potrebami, ki jih določa koncentracija IGF-I, povečuje.
The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
Odmerek je treba postopoma večati ali manjšati v skladu z individualnimi potrebami bolnika, ki jih določa koncentracija IGF-I.
The dose should be gradually increased, preferably every two days or more, to obtain the best balance between pain relief and
Odmerek je treba postopoma povečevati, priporočljivo vsaka dva dni ali več, da se doseže najboljše razmerje med učinkom lajšanja bolečine in morebitnimi neželenimi učinki.
The dose should be in line with the renal function of the elderly patient.
Pri starejših bolnikih je treba odmerek prilagoditi njihovi ledvični funkciji.
The dose should be increased at every fourth injection in four steps (0.25 ml, 0.5 ml, 0.75 ml, 1.0 ml).
Odmerek je treba povečati v štirih korakih ob vsaki četrti injekciji (0,25 ml, 0,5 ml, 0,75 ml, 1 ml).
The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated.
Odmerek je treba povečevati vsakih pet do sedem dni, dokler simptomi niso pod nadzorom, ne da bi povzročili nevzdržne neželene učinke.
The dose should be increased every five to seven days until symptoms are controlled without causing side effects that cannot be tolerated.
Odmerek je treba povečevati vsakih pet do sedem dni, dokler simptomi niso pod nadzorom, vendar zdravilo ne sme povzročiti nevzdržnih neželenih učinkov.
The dose should be increased to 28 mcg/day starting at week 2 through week 4 of the first cycle.
Odmerek je treba povečati na 28 mcg/dan, ko se začne 2. teden in do 4. tedna prvega ciklusa.
The dose should be incrementally reduced to 1 ppm for 30 minutes with close observation of systemic and central pressure, and then turned off.
Odmerek je treba postopoma zmanjšati na 1 ppm v 30 minutah, pri čemer je treba skrbno spremljati sistemski in centralni tlak, potem pa sistem izklopiti.
The dose should be raised if there is adequate tolerance and the leucocyte cystine level remains >1 nmol hemicystine/mg protein.
Odmerek je treba povečati, če je prenašanje primerno dobro in koncentracija cistina v levkocitih vztraja pri vrednosti
The dose should be raised if there is adequate tolerance and the WBC cystine level remains > 1 nmol hemicystine/mg protein.
Odmerek je treba povečati, če je prenašanje primerno dobro in koncentracija cistina v belih krvnih celicah vztraja pri vrednosti > 1 nmol hemicistina/mg beljakovin.
The dose should be reduced or treatment interrupted if a patient develops kidney or liver problems.
Če se pri bolniku pojavijo težave z ledvicami ali jetri, je treba odmerek zmanjšati ali zdravljenje prekiniti.
The dose should be reduced or treatment interrupted if the patient has certain side effects affecting the blood.
Odmerek je treba zmanjšati ali zdravljenje prekiniti, če se pri bolniku pojavijo nekateri neželeni učinki, ki vplivajo na kri.
The dose should be reduced to 2.5 mg once daily in patients with moderate or severe renal impairment.
Bolnikom z zmerno ali hudo okvaro ledvic je treba odmerek zmanjšati na 2,5 mg enkrat na dan.
The dose should be repeated after 2 hours and then at 2 – 3 hour intervals for the first 24 – 48 hours depending on the intervention performed and the clinical status of the patient.
Odmerek je treba ponoviti čez 2 uri in potem v 2- do 3-urnih presledkih v prvih 24 do 48 urah, odvisno od opravljenega posega in bolnikovega kliničnega stanja.
The dose should be repeated as long as patients respond satisfactorily and tolerate treatment.
Infuzije navedenega odmerka ponavljajte tako dolgo, dokler se bolnik zadovoljivo odziva na zdravljenje in ga dobro prenaša.
The dose should be subsequently titrated to the desired effect but should not exceed a maximum of 15mg/kg/day.
Potem je treba odmerek titrirati do želenega učinka, vendar ne sme preseči največjega odmerka 15 mg/kg/dan.
The dose should be titrated on the basis of clinical effect.
Odmerek naj se prilagaja na osnovi kliničnih učinkov.
The dose should be titrated on the basis of clinical effect.
Odmerek se prilagaja na podlagi kliničnega učinka.
The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.
Odmerek je treba titrirati do najmanjšega odmerka, pri katerem je še ohranjen učinkovit nadzor nad simptimi.
The dose should be withheld and treatment should not be resumed earlier than the next scheduled treatment in the event of: a decrease in best-corrected visual acuity (BCVA) of ≥30 letters compared with the last assessment of visual acuity; a subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is ≥50%, of the total lesion area.
Z zdravljenjem je treba prenehati in se ga ne sme ponovno začeti prej kot ob naslednjem načrtovanem odmerku v naslednjih primerih: zmanjšana najboljša korigirana ostrina vida (BCVA) > 30 črk v primerjavi z zadnjo oceno ostrine vida, krvavitev pod mrežnico, tudi v vidni jamici (fovea centralis), ali če je velikost krvavitve > 50 % celotne lezije.
The dose should be withheld and treatment should not be resumed earlier than the next scheduled treatment in the event of: a decrease in best-corrected visual acuity (BCVA) of ≥30 letters compared with the last assessment of visual acuity; an intraocular pressure of ≥30 mmHg;
Apliciranje odmerka je treba odložiti vsaj do naslednjega dogovorjenega datuma za zdravljenje v naslednjih primerih: poslabšanje najboljše ostrine vida s korekcijo (BCVA, best-corrected visual acuity) za ≥30 črk v primerjavi z zadnjim določanjem ostrine vida; intraokularni tlak ≥30 mmHg;
The dose should be withheld within the previous or next 28 days in the event of a performed or planned intraocular surgery.
Z zdravljenjem je treba prenehati 28 dni pred načrtovano intraokularno operacijo in se ga lahko nadaljuje 28. dan po opravljeni intraokularni operaciji.
The dose should not be administered intravascularly or subcutaneously.
Odmerek se ne sme injicirati intravaskularno ali subkutano.
The dose should not be doubled.
Odmerek se ne sme podvajati.
The dose should not be taken with milk or dairy products since they contain xanthine oxidase, an enzyme which metabolises 6– mercaptopurine and might therefore lead to reduced plasma concentrations of mercaptopurine.
Odmerek se ne sme jemati z mlekom ali mlečnimi izdelki, saj ti vsebujejo ksantin-oksidazo, encim, ki presnavlja 6-merkaptopurin in lahko zato povzroča manjšo koncentracijo merkaptopurina v plazmi.
The dose should not exceed 1 drop in the affected eye(s) 2 times daily.
Odmerek ne sme biti večji od 1 kapljice v prizadeto oko (očesi) dvakrat na dan.
The dose should not exceed once daily as more frequent administration may lessen the intraocular pressure lowering effect.
Odmerjanje naj ne presega dajanja enkrat dnevno, kajti pogostejše vkapanje lahko zmanjša učinek zniževanja očesnega tlaka.
The dose should not exceed one daily drop in the affected eye(s).
Odmerek ne sme preseči ene kapljice v prizadeto oko (oči) na dan.
The dose steps, however, differ between the two strengths of Tresiba.
Odmerni koraki pa se med različnima koncentracijama zdravila Tresiba razlikujejo.
The dose to be given and the interval between treatments depend on the dog’s response as well as the blood levels of certain electrolytes (sodium and potassium).
Odmerek, ki se da, in interval odmerjanja sta odvisna od odziva psa ter ravni določenih elektrolitov (natrija in kalija) v krvi.
The dose to be given depends on the dog’s bodyweight.
Odmerek, ki ga je treba dati, je odvisen od telesne mase psa.
The dose to be given depends on the patient’s bodyweight and the infusion is repeated every 3 weeks.
Odmerek, ki ga prejme bolnik, je odvisen od njegove telesne mase, infundiranje pa je treba ponoviti vsake 3 tedne.
The dose to be given is adjusted according to the patient’s weight (see the package leaflet).
Odmerek je treba prilagoditi glede na bolnikovo telesno maso (glejte navodila za uporabo).
The dose to be taken is calculated based on the active substance tegafur and the patient’s body surface area (calculated using the patient’s height and weight).
Odmerek zdravila se izračuna na podlagi zdravilne učinkovine tegafur in bolnikove telesne površine (izračunane na podlagi bolnikove višine in telesne mase).
The dose to be taken is calculated based on the patient’s body surface area (calculated using the patient’s height and weight).
Odmerek zdravila se izračuna na podlagi bolnikove telesne površine (izračunane glede na bolnikovo višino in telesno maso).
The dose to treat a Candida infection of the oesophagus is 150 mg for patients weighing more than 40 kg and 3 mg/kg per day for patients weighing 40 kg or less.
Odmerek za zdravljenja okužbe požiralnika s Candido je 150 mg za bolnike s telesno maso nad 40 kg in 3 mg/kg za bolnike s telesno maso 40 kg ali manj.
The dose to use in premature babies has not been determined.
Odmerek za prezgodaj rojene dojenčke še ni bil določen.
The dose to use is 2 mg per kilogram of the dog’s body weight.
Pri tem se uporabi odmerek, ki znaša 2 mg na kilogram telesne mase psa.
The dose to use is calculated according to the animal’s weight.
Odmerek se izračuna na podlagi telesne mase živali.
The dose to use is calculated according to the weight of the dog and the Yarvitan solution is given with the animal’s food.
Uporabljeni odmerek se izračuna glede na telesno težo psa, nato pa se raztopina Yarvitan daje psu s hrano.
The dose tray should contain the items listed below. (If not, don’t use the dose tray and consult your pharmacist).
Podstavek z zdravilom mora vsebovati vse spodaj navedene pripomočke (če jih ne, ne uporabite zdravila in se posvetujte s farmacevtom).
The dose volume for the reconstituted NovoThirteen diluted with 6 ml sodium chloride 0.9%, solution for injection can be calculated by using the below formula:
Velikost odmerka pripravljenega zdravila NovoThirteen, razredčenega s 6,0 ml 0,9 % raztopine natrijevega klorida za injiciranje, je mogoče izračunati po naslednji formuli:
The dose volume for the reconstituted NovoThirteen diluted with 6.0 ml sodium chloride 0.9% solution for injection can be calculated by using the below formula:
Velikost odmerka pripravljenega zdravila NovoThirteen, razredčenega s 6,0 ml 0,9 % raztopine natrijevega klorida za injiciranje, je mogoče izračunati po naslednji formuli:
The dose volume in millilitres should be calculated based on body weight for each patient using the following formula: Dose volume in ml = 0.042 x subject bw (kg) if bw > 24 kg or dose volume in ml = 0.117 x bw (kg) if bw < 24 kg)).
Velikost odmerka v mililitrih je treba za vsakega bolnika izračunati glede na telesno maso po naslednji formuli: velikost odmerka v ml = 0,042 x bolnikova telesna masa (v kg), če je telesna masa > 24 kg ali velikost odmerka v ml = 0,117 x telesna masa (kg), če je telesna masa < 24 kg).
The dose volume of atipamezole at the concentration of 5 mg/ml equals one- tenth (1/10) the volume of Dexdomitor 0.1 mg/ml that was given to the cat.
Volumen odmerka atipamezola v koncentraciji 5 mg/ml je enak eni desetini (1/10) volumna odmerka Dexdomitorja 0,1 mg/ml, ki je bil dan mački.
The dose volume of atipamezole at the concentration of 5 mg/ml is one fifth (1/5) of the dose volume of Dexdomitor 0.1 mg/ml that was given to the dog, regardless of route of administration of Dexdomitor.
Volumen odmerka atipamezola pri koncentraciji 5 mg/ml ustreza eni petini (1/5) volumna odmerka Dexdomitorja 0,1 mg/ml, ki je bil dan psu, ne glede na način uporabe Dexdomitorja.
The dose volume of atipamezole at the concentration of 5mg/ml equals one-half the volume of Dexdomitor that was given to the cat.
Volumen odmerka atipamezola v koncentraciji 5 mg/ml je enak eni polovici volumna odmerka Dexdomitorja, ki je bil dan mački.
The dose was increased at weekly intervals by increments of 200 micrograms given twice daily to determine the individualised maintenance dose (200–1,600 micrograms twice daily).
Odmerek se je postopoma povečeval v tedenskih intervalih po 200 mikrogramov dvakrat na dan za določitev individualiziranega vzdrževalnega odmerka (200–1.600 mikrogramov dvakrat na dan).
The dose was increased starting on Day 4 and the highest target dose (390 mg levodopa/97.5 mg carbidopa TID) was achieved by Day 22.
Odmerek so povečali 4. dan, največji ciljni odmerek (390 mg levodope/97,5 mg karbidope trikrat na dan) pa je bil dosežen do 22. dneva.
The dose will be adjusted by the doctor according to your child’s condition.
Odmerek bo zdravnik prilagodil glede na stanje vašega otroka.
The dose will be increased every 5-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).
Odmerek boste po zdravnikovih navodilih vsakih 5 do 7 dni povečevali, dokler ne bodo simptomi minili (vzdrževalni odmerek).
The dose will depend on your height and weight.
Odmerek je odvisen od telesne višine in mase.
The dose will then be further adjusted by your doctor depending on your body’s response.
Odmerek bo zdravnik nato dodatno prilagodil glede na odziv vašega telesa.
The dose window shows the number of Toujeo units to be injected.
Odmerno okence kaže število enot zdravila Toujeo, ki bodo injicirane.
The dose you need will be calculated by your doctor.
Odmerek, ki ga potrebuete, bo izračunal zdravnik.
The dose you or your child receives is based on your or your child’s body weight.
Odmerek, ki ga bosta vi oziroma vaš otrok prejela, je odvisen od vaše oziroma otrokove telesne mase.
The dose, administration frequency and duration of treatment depend on the severity of the protein C deficiency as well as on your clinical condition and on your plasma level of protein C. They should be adjusted accordingly on the basis of clinical effectiveness and laboratory assessment.
Odmerek, pogostnost uporabe in trajanje zdravljenja so odvisni od stopnje pomanjkanja proteina C vašega kliničnega stanja ter vaše plazemske koncentracije proteina C. V skladu s klinično učinkovitostjo in laboratorijskimi izvidi jih moramo ustrezno prilagajati.
The dose, and how often it is given, as well as the length of treatment, are adjusted depending on the patient’s condition and requirements, and the degree of danger posed by the bleeding.
Odmerek, pogostnost dajanja in trajanje zdravljenja se prilagodijo glede na bolnikovo stanje in potrebe ter stopnjo nevarnosti, ki jo krvavitev zanj pomeni.
The dose, frequency and duration of the substitution therapy must be individualised according to the patient's needs (weight, severity of disorder of the haemostatic function, the site and extent of the bleeding, the presence of inhibitors, and the factor VIII level desired).
Odmerek, pogostnost in trajanje nadomestnega zdravljenja je treba prilagoditi potrebam posameznega bolnika (odvisno od telesne mase, stopnje motnje strjevanja krvi, mesta in obsega krvavitve, prisotnosti inhibitorjev in od želene ravni faktorja VIII).
The dose, frequency, route, and length of treatment depends on the weight and type of animal and the condition to be treated.
Odmerek, pogostost odmerjanja, način uporabe zdravila in trajanje zdravljenja so odvisni od telesne mase živali, živalske vrste in bolezenskega stanja, ki ga zdravimo.
The dose, the frequency of injection and how long it is used for also depend on why Abseamed is being used and on the patient’s bodyweight, and are adjusted according to the patient’s response.
Odmerek, pogostost injiciranja in trajanje uporabe zdravila Abseamed so odvisni tudi od razloga za njegovo uporabo in bolnikove telesne mase ter jih je treba prilagoditi bolnikovemu odzivu.
The dose, the frequency of injection and how long it is used for also depend on why Binocrit is being used and on the patient’s bodyweight, and are adjusted according to the patient’s response.
Odmerek, pogostost injiciranja in trajanje uporabe zdravila Binocrit so odvisni od razloga za njegovo uporabo in bolnikove telesne mase ter jih je treba prilagoditi bolnikovemu odzivu.
The dose, the frequency of injection and how long Retacrit is used for depend on why it is being used, and are adjusted according to the patient’s response.
Odmerek, pogostnost injiciranja in trajanje zdravljenja z zdravilom Retacrit so odvisni od namena uporabe zdravila in jih je treba prilagoditi bolnikovemu odzivu.
The dose, the frequency of injection and how long Silapo is used for depend on why it is being used and the patient’s bodyweight, and are adjusted according to the patient’s response.
Odmerek, pogostost injiciranja in trajanje uporabe zdravila Silapo so odvisni od razloga za uporabo tega zdravila in bolnikove telesne mase ter jih je treba prilagoditi bolnikovemu odzivu.
The dose, the frequency of injection, and how long it is used for depend on why NeoRecormon is used, and are adjusted according to the patient’s response to treatment.
Odmerek, pogostost injiciranja in trajanje uporabe zdravila NeoRecormon so odvisni od razloga za uporabo tega zdravila in jih je treba prilagoditi odzivu bolnika.
The dose, which has been adjusted for you and your condition, will generally be between 150 mg (7.5 ml) and 600 mg (30 ml) each day.
Odmerek, prilagojen vam in vaši bolezni, bo praviloma med 150 mg (7,5 ml) in 600 mg (30 ml) na dan.
The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day.
Odmerek, ki ga je prilagodil vam in vaši bolezni, bo praviloma med 150 mg in 600 mg na dan.
The dose-related QTc interval prolongation potential of Fareston should also be taken into account in cases of overdose.
V primerih prekomernega odmerjanja zdravila je treba upoštevati možnost podaljšanja intervala QT c glede na velikost odmerka zdravila Fareston.
The dose-response curve for tocilizumab flattens at higher exposure, resulting in smaller efficacy gains for each incremental increase in tocilizumab concentration such that clinically meaningful increases in efficacy were not demonstrated in patients treated with > 800 mg of tocilizumab.
Krivulja odmerek-odziv za tocilizumab je pri večji izpostavljenosti bolj položna, kar pomeni manjše poraste učinkovitosti pri vsakem nadaljnjem povečanju koncentracije tocilizumaba; tako pri bolnikih, zdravljenih z več kot 800 mg tocilizumaba, niso dokazali klinično pomembnih porastov učikovitosti.
The doses and duration of treatment depend on to the patient’s response to the medicine.
Odmerki in trajanje zdravljenja so odvisni od odziva bolnika na zdravilo.
The doses are adjusted until the required level of sedation is attained.
Odmerki se prilagajajo, dokler ni dosežena želena stopnja sedacije.
The doses described below are stated in International Units (IU) and millilitres (ml).
Odmerki, opisani spodaj, so navedeni v mednarodnih enotah (i.e.) in mililitrih (ml).
The doses evaluated in the clinical studies ranged from a single vial of 2100 U (corresponding to 18-40 U/kg), to 50 and 100 U/kg.
Odmerki, ki so jih proučevali v kliničnih študijah, segajo od ene viale 2100 e. (kar ustreza 18–40 e./kg) do 50 in 100 e./kg.
The doses may need to be lower in patients who have kidney problems.
Pri bolnikih z ledvičnimi težavami bodo morda potrebni nižji odmerki.
The doses of atazanavir oral powder and ritonavir for paediatric patients are based on body weight as shown in Table 1.
Odmerek atazanavirja v obliki peroralnega praška pri pediatričnih bolnikih temelji na njihovi telesni masi, kot prikazuje preglednica 1.
The doses of other antiparkinsonian medicinal products may need to be adjusted when Levodopa/Carbidopa/Entacapone Orion treatment is substituted for a patient currently not treated with entacapone.
Kadar zdravilo Levodopa/Carbidopa/Entacapone Orion nadomešča terapijo pri bolniku, ki trenutno ne prejema entakapona, bo odmerke drugih antiparkinsonskih zdravil morda treba ustrezno prilagoditi.
The doses of paritaprevir were 100 mg and 200 mg and ombitasvir 25 mg.
Odmerki paritaprevirja so bili 100 mg in 200 mg ter ombitasvirja 25 mg.
The doses recommended in patients of at least 75 years old are as follows:
Za bolnike, ki so stari najmanj 75 let, priporočamo naslednje odmerke:
The doses should also be lower in patients with mildly or moderately reduced liver function.
Odmerek zdravila je treba zmanjšati tudi pri bolnikih z lažjo ali zmerno okvaro jeter.
The doses should be given as either one spray or two sprays of the same strength.
Zdravilo je treba odmerjati bodisi v enem vpihu pršila ali dveh vpihih enake jakosti.